Please login to the form below
13
Revenue 2017Bristol-Myers Squibb
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.
2019: CRISPR and therapeutic gene editing comes of age
The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the
Merck puts prostate cancer firmly in Keytruda’s sights
Merck has competition in this area of course, and arch-rival in the cancer immunotherapy category, Bristol Myers Squibb, reported results at ASCO GU with its double immunotherapy combination of
CEOs agree to Congressional grilling on US drug prices
Now Pfizer’s Albert Bourla, Merck’s Ken Frazier, Sanofi’s Olivier Brandicourt and Bristol-Myers Squibb’s Giovanni Caforio have now all confirmed they will attend the finance committee hearings
Another amyloid bust as Roche pulls crenezumab trials
AD have also yielded disappointing results for companies including TauRx, Zeltia, Bristol-Myers Squibb and Allon/Paladin Labs.
BMS isn’t phased by Opdivo’s slowing growth – for now
Lung cancer filing withdrawn after FDA reservations. Bristol-Myers Squibb’s fourth-quarter results showed a healthy sales increase for immuno-oncology blockbuster Opdivo, but there are signs that anxiety is
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Digital Account Director
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
-
Project Manager/ Account Manager
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- Drug launches to watch in 2019
- Novartis first to benefit from NICE advice on ‘patient preference’
- Immuno-oncology in 2019: the rapid evolution continues
- GW Pharma's cannabis-based medicine to be tested in dementia
- Novartis’ Egatan gains US approval for neglected tropical disease
- AZ says dropping MedImmune will help ‘streamline’ its R&D
- How Medisafe is using AI to improve patient adherence
- KYNE expands presence to London
- Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader
- Lilly, Pfizer say NGF drug works in back pain too
- Intercept NASH drug closes in on FDA approval
- As government rushes through no-deal legislation, UK biotech repeats Brexit plea
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
- Cell and gene therapy
- Tackling the manufacturing cost and complexity challenges...
- 2019: CRISPR and therapeutic gene editing comes of age
- Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
Quick links
Infographics
